167 related articles for article (PubMed ID: 38243274)
1. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
Zhang KY; Duan WW; Luo YB; Li Y; Hu J; Yang H
Orphanet J Rare Dis; 2024 Jan; 19(1):19. PubMed ID: 38243274
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis.
Ozawa Y; Uzawa A; Kanai T; Oda F; Yasuda M; Kawaguchi N; Himuro K; Kuwabara S
J Neurol Sci; 2019 Jul; 402():12-15. PubMed ID: 31100651
[TBL] [Abstract][Full Text] [Related]
3. Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Uzawa A; Suzuki S; Kuwabara S; Akamine H; Onishi Y; Yasuda M; Ozawa Y; Kawaguchi N; Kubota T; Takahashi MP; Suzuki Y; Watanabe G; Kimura T; Sugimoto T; Samukawa M; Minami N; Masuda M; Konno S; Nagane Y; Utsugisawa K
Neurotherapeutics; 2023 Mar; 20(2):518-523. PubMed ID: 36607596
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
5. Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis.
Sugimoto T; Ochi K; Ishikawa R; Tazuma T; Hayashi M; Mine N; Naito H; Nomura E; Kohriyama T; Yamawaki T
J Neurol Sci; 2020 May; 412():116740. PubMed ID: 32145521
[TBL] [Abstract][Full Text] [Related]
6. Ocular myasthenia gravis - How effective is low dose prednisone long term?
Verma R; Wolfe GI; Kupersmith MJ
J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
8. Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients.
Fan Z; Li Z; Shen F; Zhang X; Lei L; Su S; Lu Y; Di L; Wang M; Xu M; Da Y
Front Neurol; 2020; 11():594152. PubMed ID: 33193063
[No Abstract] [Full Text] [Related]
9. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
11. Response to treatment in pediatric ocular myasthenia gravis.
Xu L; Castro D; Reisch JS; Iannaccone ST
Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.
Qiu L; Chen P; Ou C; Deng J; Huang Z; Lin Z; Ma Q; Huang X; Yu L; Ran H; Liu W
Acta Neurol Belg; 2024 Feb; 124(1):175-182. PubMed ID: 37656361
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis].
Wang RY; Chen H; Huang ZX; Chen Y; Zhong JM
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1034-1039. PubMed ID: 37905760
[TBL] [Abstract][Full Text] [Related]
14. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study.
Lindberg C; Andersen O; Lefvert AK
Acta Neurol Scand; 1998 Jun; 97(6):370-3. PubMed ID: 9669469
[TBL] [Abstract][Full Text] [Related]
15. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
18. [Analysis for the effect of different regimens on ocular myasthenia gravis in children].
Liu C; Wang X; Xie L; Peng J; Wu L; Zheng X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1275-1279. PubMed ID: 29187654
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
20. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
